首页 > 最新文献

European Journal of Integrative Medicine最新文献

英文 中文
Clinical efficacy and safety of Shensong Yangxin capsule-antiarrhythmic drug combination for paroxysmal atrial fibrillation: A meta-analysis of randomized controlled trials 参松养心胶囊联合抗心律失常药物治疗阵发性心房颤动的临床疗效和安全性:一项随机对照试验的meta分析
IF 2.5 4区 医学 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2023-12-01 DOI: 10.1016/j.eujim.2023.102320
Xinfu Cao , Zhenhua Gu , Yi Sun , Yuqiao Chen , Chao Tang , Hongwen Yu , Xiaolong Li

Introduction

Shensong Yangxin Capsule (SSYX) is a famous traditional Chinese patent medicine produced in China for the treatment of arrhythmia. Recently, China released a series of randomized controlled trials (RCTs) using SSYX combined with antiarrhythmic drugs (ADs) for the treatment of paroxysmal atrial fibrillation (PAF). However, these RCTs have not been systematically evaluated. The purpose of this review was to assess the effectiveness and safety of SSYX combined with AD (SSYX-AD) in the treatment of PAF.

Methods

RCTs of SSYX-AD in the treatment of PAF were collected by searching the Chinese Knowledge Infrastructure Database (CNKI), PubMed, Chinese Scientific Journal Database (VIP), Wanfang Database, Cochrane Library, China Biomedical Database Network (CBM), Excerpt Medica Database (EMBASE), and clinical trial platforms such as the UK National Research Registry (NRR), the World Health Organization Clinical Trial Registry (ICTRP), and the Chinese Clinical Trial Registry (CCTR) from its creation until July 1, 2023. The primary outcome was the effective rate. The secondary outcomes were the frequency of atrial fibrillation (FAF), left atrial diameter (LAD), P wave dispersion (PWD), adverse reactions (ADRs), left ventricular ejection fraction (LVEF), and sinus rhythm maintenance rate (SRMR). The quality assessment of RCTs was completed using the Cochrane risk-of-bias tool, and the meta-analysis was completed using RevMan 5.3 software. This review was conducted in accordance with the PROSPERO-registered protocol (number: CRD42023413442).

Results

The review included a total of 29 RCTs including 2766 patients. The review showed that the SSYX-AD group had more advantages than AD group in improving the effective rate [RR=1.18; 95 % CI (1.12, 1.24); p < 0.01], LVEF [MD =3.40; 95 % CI (0.91, 5.88); p = 0.007], SRMA [RR=1.38; 95 % CI (1.22, 1.57); p < 0.01], and was superior to AD alone in reducing the FAF [MD=2.89; 95 % CI (1.57, 4.21); p < 0.01], LAD [MD=2.44; 95 % CI (0.85, 4.03); p < 0.01], PWD [MD = 4.90; 95 % CI (2.81, 6.99); p < 0.05], and ADRs [RR=0.41; 95 % CI (0.29, 0.58); p < 0.01].

Conclusions

Despite the apparently positive outcomes presented, due to the low methodological quality of the included RCTs there was insufficient evidence to recommend routine use of SSYX-AD for PAF. The aggregate effect must be validated by additional well-designed, adequately sampled, and methodologically sound clinical studies.

参松养心胶囊(SSYX)是中国生产的治疗心律失常的著名中成药。最近,中国发布了一系列使用SSYX联合抗心律失常药物(ADs)治疗阵发性心房颤动(PAF)的随机对照试验(RCTs)。然而,这些随机对照试验尚未得到系统评价。本综述的目的是评估SSYX联合AD (SSYX-AD)治疗PAF的有效性和安全性。方法通过检索中国知识基础数据库(CNKI)、PubMed、中国科学期刊数据库(VIP)、万方数据库、Cochrane图书馆、中国生物医学数据库网(CBM)、摘录医学数据库(EMBASE)以及英国国家研究注册中心(NRR)、世界卫生组织临床试验注册中心(ICTRP)、中国临床试验注册中心(CCTR)从成立到2023年7月1日。主要观察指标为有效率。次要指标为房颤频率(FAF)、左房径(LAD)、P波离散度(PWD)、不良反应(adr)、左室射血分数(LVEF)、窦性心律维持率(SRMR)。采用Cochrane风险偏倚工具完成rct质量评价,采用RevMan 5.3软件完成meta分析。本综述按照普洛斯彼罗注册方案(编号:CRD42023413442)进行。结果共纳入29项随机对照试验,共纳入2766例患者。综述显示,SSYX-AD组在提高有效率方面优于AD组[RR=1.18;95% ci (1.12, 1.24);p & lt;0.01], lvef [md =3.40;95% ci (0.91, 5.88);p = 0.007],SRMA [RR=1.38;95% ci (1.22, 1.57);p & lt;0.01],且在降低FAF方面优于单独AD [MD=2.89;95% ci (1.57, 4.21);p & lt;[0.01], lad [md =2.44;95% ci (0.85, 4.03);p & lt;0.01], PWD [md = 4.90;95% ci (2.81, 6.99);p & lt;0.05], adr [RR=0.41;95% ci (0.29, 0.58);p & lt;0.01]。结论:尽管出现了明显的积极结果,但纳入的rct的方法学质量较低,表明没有足够的证据推荐常规使用SSYX-AD治疗PAF。总体效应必须通过额外的精心设计、充分采样和方法学上合理的临床研究来验证。
{"title":"Clinical efficacy and safety of Shensong Yangxin capsule-antiarrhythmic drug combination for paroxysmal atrial fibrillation: A meta-analysis of randomized controlled trials","authors":"Xinfu Cao ,&nbsp;Zhenhua Gu ,&nbsp;Yi Sun ,&nbsp;Yuqiao Chen ,&nbsp;Chao Tang ,&nbsp;Hongwen Yu ,&nbsp;Xiaolong Li","doi":"10.1016/j.eujim.2023.102320","DOIUrl":"10.1016/j.eujim.2023.102320","url":null,"abstract":"<div><h3>Introduction</h3><p>Shensong Yangxin Capsule (SSYX) is a famous traditional Chinese patent medicine produced in China for the treatment of arrhythmia. Recently, China released a series of randomized controlled trials (RCTs) using SSYX combined with antiarrhythmic drugs (ADs) for the treatment of paroxysmal atrial fibrillation (PAF). However, these RCTs have not been systematically evaluated. The purpose of this review was to assess the effectiveness and safety of SSYX combined with AD (SSYX-AD) in the treatment of PAF.</p></div><div><h3>Methods</h3><p>RCTs of SSYX-AD in the treatment of PAF were collected by searching the Chinese Knowledge Infrastructure Database (CNKI), PubMed, Chinese Scientific Journal Database (VIP), Wanfang Database, Cochrane Library, China Biomedical Database Network (CBM), Excerpt Medica Database (EMBASE), and clinical trial platforms such as the UK National Research Registry (NRR), the World Health Organization Clinical Trial Registry (ICTRP), and the Chinese Clinical Trial Registry (CCTR) from its creation until July 1, 2023. The primary outcome was the effective rate. The secondary outcomes were the frequency of atrial fibrillation (FAF), left atrial diameter (LAD), P wave dispersion (PWD), adverse reactions (ADRs), left ventricular ejection fraction (LVEF), and sinus rhythm maintenance rate (SRMR). The quality assessment of RCTs was completed using the Cochrane risk-of-bias tool, and the meta-analysis was completed using RevMan 5.3 software. This review was conducted in accordance with the PROSPERO-registered protocol (number: CRD42023413442).</p></div><div><h3>Results</h3><p>The review included a total of 29 RCTs including 2766 patients. The review showed that the SSYX-AD group had more advantages than AD group in improving the effective rate [RR=1.18; 95 % CI (1.12, 1.24); <em>p</em> &lt; 0.01], LVEF [MD =3.40; 95 % CI (0.91, 5.88); <em>p</em> = 0.007], SRMA [RR=1.38; 95 % CI (1.22, 1.57); <em>p</em> &lt; 0.01], and was superior to AD alone in reducing the FAF [MD=2.89; 95 % CI (1.57, 4.21); <em>p</em> &lt; 0.01], LAD [MD=2.44; 95 % CI (0.85, 4.03); <em>p</em> &lt; 0.01], PWD [MD = 4.90; 95 % CI (2.81, 6.99); <em>p</em> &lt; 0.05], and ADRs [RR=0.41; 95 % CI (0.29, 0.58); <em>p</em> &lt; 0.01].</p></div><div><h3>Conclusions</h3><p>Despite the apparently positive outcomes presented, due to the low methodological quality of the included RCTs there was insufficient evidence to recommend routine use of SSYX-AD for PAF. The aggregate effect must be validated by additional well-designed, adequately sampled, and methodologically sound clinical studies.</p></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"65 ","pages":"Article 102320"},"PeriodicalIF":2.5,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138508568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of Shengmai injection for chronic cor pulmonale: A systematic review with meta-analysis and trial sequential analysis of 31 randomized controlled trials 生脉注射液治疗慢性肺心病的疗效和安全性:31项随机对照试验荟萃分析和试验序贯分析的系统评价
IF 2.5 4区 医学 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2023-11-23 DOI: 10.1016/j.eujim.2023.102318
Xunxun Yuan , Xianjie Feng , Jun He , Sheng Xu , Xu Zhou , Lihua Wang

Introduction

This study aimed to systematically evaluate the efficacy and safety of Shengmai injection (Radix ginseng, Radix ophiopogonis, and Fructus Schisandrae chinensis) as an adjunct to conventional medicine in the treatment of chronic cor pulmonale.

Methods

A search of ten databases was conducted up to March 27, 2023, to identify randomized controlled trials that assessed the efficacy of Shengmai injection plus conventional medicine versus conventional medicine alone in the treatment of chronic cor pulmonale. Meta-analysis was performed using RevMan version 5.4, with risk ratios (RRs), mean differences (MDs), and 95 % confidence intervals (CIs) used as effect measures. Trial sequential analyses were conducted to quantify the statistical reliability of the data in the studies.

Results

A total of 31 studies involving 3,036 patients were included in the meta-analysis. The results showed that Shengmai injection combined with conventional therapies significantly improved the response to treatment (RR 1.24, CIs 1.19 to 1.29) as well as heart function (e.g., left ventricular ejection fraction: MD 8.14 % [CIs 2.33 to 13.95]; right ventricular ejection fraction: MD 8.51 % [CIs 3.61 to 13.41], stroke volume: MD 12.38 mL [CIs 4.80 to 19.96], cardiac output: MD 0.35 L/min, [CIs 0.19 to 0.50], cardiac index: MD 0.45 L/min·m2, [CIs 0.19 to 0.72]), blood gas indicators (SaO2: MD 4.18 % [CIs 3.12 to 5.25], PaO2: MD 5.63 mmHg [CIs 4.26 to 7.00]), and lung function (FEV1: MD 0.40 L [CIs 0.26 to 0.53], FEV1/FVC: MD 10.10 % [CIs 7.43 to 12.77]) in patients with cor pulmonale. Additionally, no significant improvement was observed in creatine kinase isoenzyme- myocardial band or plasma viscosity compared with the controls. Two cases (4 %) of mild adverse events (dry mouth) possibly related to Shengmai injection were reported, but no serious adverse events were observed.

Conclusions

Shengmai injection may be an effective supplemental therapy for chronic cor pulmonale, potentially improving treatment response, heart and lung functioning, blood gas analysis, and hemorheological indicators, with an acceptable safety profile. However, the risk of selection bias and high heterogeneity in some studies highlight the need for further multicenter, large-sample randomized controlled trials to validate these findings.

本研究旨在系统评价生脉注射液(参、麦冬、五味子)作为常规药物辅助治疗慢性肺心病的疗效和安全性。方法检索截至2023年3月27日的10个数据库,筛选随机对照试验,评价生脉注射液联合常规药物与单独常规药物治疗慢性肺心病的疗效。采用RevMan version 5.4进行meta分析,采用风险比(rr)、平均差异(MDs)和95%置信区间(ci)作为效果度量。进行试验序列分析以量化研究中数据的统计可靠性。结果meta分析共纳入31项研究,涉及3036例患者。结果显示,生脉注射液联合常规治疗可显著改善治疗反应(RR = 1.24, CIs = 1.19 ~ 1.29)和心功能(如左室射血分数:MD = 8.14% [CIs = 2.33 ~ 13.95];肺心病患者右心室射血分数:MD 8.51% [CIs 3.61 ~ 13.41],卒中容积:MD 12.38 mL [CIs 4.80 ~ 19.96],心输出量:MD 0.35 L/min, [CIs 0.19 ~ 0.50],心脏指数:MD 0.45 L/min·m2, [CIs 0.19 ~ 0.72]),血气指标(SaO2: MD 4.18% [CIs 3.12 ~ 5.25], PaO2: MD 5.63 mmHg [CIs 4.26 ~ 7.00]),肺功能(FEV1: MD 0.40 L [CIs 0.26 ~ 0.53], FEV1/FVC: MD 10.10% [CIs 7.43 ~ 12.77])。此外,与对照组相比,肌酸激酶同工酶-心肌带或血浆粘度没有明显改善。报告可能与生脉注射液有关的轻度不良事件(口干)2例(4%),未见严重不良事件。结论生脉注射液可能是慢性肺心病的有效补充治疗,可改善治疗效果、心肺功能、血气分析和血液流变学指标,安全性可接受。然而,一些研究存在选择偏倚和高度异质性的风险,需要进一步进行多中心、大样本随机对照试验来验证这些发现。
{"title":"Efficacy and safety of Shengmai injection for chronic cor pulmonale: A systematic review with meta-analysis and trial sequential analysis of 31 randomized controlled trials","authors":"Xunxun Yuan ,&nbsp;Xianjie Feng ,&nbsp;Jun He ,&nbsp;Sheng Xu ,&nbsp;Xu Zhou ,&nbsp;Lihua Wang","doi":"10.1016/j.eujim.2023.102318","DOIUrl":"10.1016/j.eujim.2023.102318","url":null,"abstract":"<div><h3>Introduction</h3><p>This study aimed to systematically evaluate the efficacy and safety of Shengmai injection (<em>Radix ginseng, Radix ophiopogonis,</em> and <em>Fructus Schisandrae chinensis</em>) as an adjunct to conventional medicine in the treatment of chronic cor pulmonale.</p></div><div><h3>Methods</h3><p>A search of ten databases was conducted up to March 27, 2023, to identify randomized controlled trials that assessed the efficacy of Shengmai injection plus conventional medicine versus conventional medicine alone in the treatment of chronic cor pulmonale. Meta-analysis was performed using RevMan version 5.4, with risk ratios (RRs), mean differences (MDs), and 95 % confidence intervals (CIs) used as effect measures. Trial sequential analyses were conducted to quantify the statistical reliability of the data in the studies.</p></div><div><h3>Results</h3><p>A total of 31 studies involving 3,036 patients were included in the meta-analysis. The results showed that Shengmai injection combined with conventional therapies significantly improved the response to treatment (RR 1.24, CIs 1.19 to 1.29) as well as heart function (e.g., left ventricular ejection fraction: MD 8.14 % [CIs 2.33 to 13.95]; right ventricular ejection fraction: MD 8.51 % [CIs 3.61 to 13.41], stroke volume: MD 12.38 mL [CIs 4.80 to 19.96], cardiac output: MD 0.35 L/min, [CIs 0.19 to 0.50], cardiac index: MD 0.45 L/min·m<sup>2</sup>, [CIs 0.19 to 0.72]), blood gas indicators (SaO<sub>2</sub>: MD 4.18 % [CIs 3.12 to 5.25], PaO<sub>2</sub>: MD 5.63 mmHg [CIs 4.26 to 7.00]), and lung function (FEV<sub>1</sub>: MD 0.40 L [CIs 0.26 to 0.53], FEV<sub>1</sub>/FVC: MD 10.10 % [CIs 7.43 to 12.77]) in patients with cor pulmonale. Additionally, no significant improvement was observed in creatine kinase isoenzyme- myocardial band or plasma viscosity compared with the controls. Two cases (4 %) of mild adverse events (dry mouth) possibly related to Shengmai injection were reported, but no serious adverse events were observed.</p></div><div><h3>Conclusions</h3><p>Shengmai injection may be an effective supplemental therapy for chronic cor pulmonale, potentially improving treatment response, heart and lung functioning, blood gas analysis, and hemorheological indicators, with an acceptable safety profile. However, the risk of selection bias and high heterogeneity in some studies highlight the need for further multicenter, large-sample randomized controlled trials to validate these findings.</p></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"65 ","pages":"Article 102318"},"PeriodicalIF":2.5,"publicationDate":"2023-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S187638202300094X/pdfft?md5=a2a653895ad67f5c3f56c0a2df40b625&pid=1-s2.0-S187638202300094X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138508571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of drivers and affecting factors in the future of Persian medicine: The cross-impact analysis method 确定波斯医学未来的驱动因素和影响因素:交叉影响分析方法
IF 2.5 4区 医学 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2023-11-23 DOI: 10.1016/j.eujim.2023.102316
Mohammad Hossain Mehrolhassani , Mohammad Setayesh , Vahid Yazdi-Feyzabadi , Rohaneh Rahimisadegh

Introduction

Persian medicine is a holistic medical school with deep roots. It has a high educational, research, and therapeutic capacity and has been the focus of Iran's general health policies in recent years. Futures studies aid policymakers and health managers in creating normative scenarios and developing action plans using various techniques. This study aimed to identify important drivers and factors that affect the future of the Persian medicine system.

Method

This qualitative research was conducted with a futures studies approach, using the Cross-Impact Analysis (CIA) in three main steps. The first and second steps were conducted using interviews and focus group discussions. In the first step, 15 semi-structured interviews were conducted with Persian medicine experts to identify all factors affecting the future of Persian medicine. In the second step, we held three focus group discussions with 9 interviewees from step one with national-level influence to determine the influence and dependence of each factor. The third step was performed using the matrix CIA and MICMAC to identify the key factors affecting the future of Persian medicine.

Results

Sixty five variables affecting the future of Persian medicine were identified, 36 related to the health system, and 29 to external factors. Factors such as globalization, knowledge-based economy, the spread of non-communicable and chronic diseases, as well as people's views and attitudes towards Persian medicine, are considered key drivers and variables that will affect the future of the Persian medicine system. The Iranian development plans as a two-dimensional and risk factor are crucial in establishing Persian medicine.

Conclusion

The future of the Persian medicine system is relatively stable. The pattern of the Iranian development plans is considered the most important two-faceted factor as a risk factor in the establishment of the Persian medicine system. It is suggested that the position of the Persian medicine system in the Iranian development plans be made more prominent.

波斯医学是一个有着深厚根基的整体医学流派。它具有很高的教育、研究和治疗能力,近年来一直是国家一般卫生政策的重点。未来研究帮助决策者和卫生管理人员使用各种技术创建规范情景和制定行动计划。本研究旨在确定影响波斯医学系统未来的重要驱动因素和因素。方法本定性研究采用未来研究方法,采用交叉影响分析(CIA)分为三个主要步骤。第一和第二步是通过访谈和焦点小组讨论进行的。在第一步,与波斯医学专家进行了15次半结构化访谈,以确定影响波斯医学未来的所有因素。在第二步中,我们与第一步中具有国家级影响力的9位受访者进行了三次焦点小组讨论,以确定每个因素的影响和依赖性。第三步是使用矩阵CIA和MICMAC来确定影响波斯医学未来的关键因素。结果影响波斯医学未来发展的65个变量中,与卫生系统相关的变量36个,与外部因素相关的变量29个。全球化、知识经济、非传染性疾病和慢性病的传播以及人们对波斯医学的看法和态度等因素被认为是影响波斯医学系统未来的关键驱动因素和变量。伊朗的发展计划是一个二维和风险因素,对建立波斯医学至关重要。结论波斯医学体系的发展前景相对稳定。伊朗发展计划的模式被认为是波斯医学体系建立过程中最重要的两个方面的风险因素。建议波斯医学体系在伊朗发展计划中的地位应更加突出。
{"title":"Identification of drivers and affecting factors in the future of Persian medicine: The cross-impact analysis method","authors":"Mohammad Hossain Mehrolhassani ,&nbsp;Mohammad Setayesh ,&nbsp;Vahid Yazdi-Feyzabadi ,&nbsp;Rohaneh Rahimisadegh","doi":"10.1016/j.eujim.2023.102316","DOIUrl":"10.1016/j.eujim.2023.102316","url":null,"abstract":"<div><h3>Introduction</h3><p>Persian medicine is a holistic medical school with deep roots. It has a high educational, research, and therapeutic capacity and has been the focus of Iran's general health policies in recent years. Futures studies aid policymakers and health managers in creating normative scenarios and developing action plans using various techniques. This study aimed to identify important drivers and factors that affect the future of the Persian medicine system.</p></div><div><h3>Method</h3><p>This qualitative research was conducted with a futures studies approach, using the Cross-Impact Analysis (CIA) in three main steps. The first and second steps were conducted using interviews and focus group discussions. In the first step, 15 semi-structured interviews were conducted with Persian medicine experts to identify all factors affecting the future of Persian medicine. In the second step, we held three focus group discussions with 9 interviewees from step one with national-level influence to determine the influence and dependence of each factor. The third step was performed using the matrix CIA and MICMAC to identify the key factors affecting the future of Persian medicine.</p></div><div><h3>Results</h3><p>Sixty five variables affecting the future of Persian medicine were identified, 36 related to the health system, and 29 to external factors. Factors such as globalization, knowledge-based economy, the spread of non-communicable and chronic diseases, as well as people's views and attitudes towards Persian medicine, are considered key drivers and variables that will affect the future of the Persian medicine system. The Iranian development plans as a two-dimensional and risk factor are crucial in establishing Persian medicine.</p></div><div><h3>Conclusion</h3><p>The future of the Persian medicine system is relatively stable. The pattern of the Iranian development plans is considered the most important two-faceted factor as a risk factor in the establishment of the Persian medicine system. It is suggested that the position of the Persian medicine system in the Iranian development plans be made more prominent.</p></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"65 ","pages":"Article 102316"},"PeriodicalIF":2.5,"publicationDate":"2023-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138508577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of Chinese herbal medicine on pregnancy outcomes of women with PCOS undergoing in vitro fertilization and embryo transfer: A retrospective cohort study 中药对PCOS患者体外受精和胚胎移植妊娠结局的影响:一项回顾性队列研究
IF 2.5 4区 医学 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2023-11-23 DOI: 10.1016/j.eujim.2023.102317
Minchen Dai , Biwei Shi , Xian Zhang , Yinger Gu , Fangfang Wang , Jue Zhou , Fan Qu

Introduction

Chinese herbal medicine is widely used for treating polycystic ovary syndrome (PCOS). The present study aimed to explore the effects of Bu-Shen-Jian-Pi Formula, a Chinese herbal medicine formula, on the pregnancy outcomes of women with PCOS undergoing in vitro fertilization and embryo transfer (IVF-ET) based on a retrospective cohort study.

Methods

One hundred and forty-six females with PCOS undergoing IVF-ET were included in the study from Women's Hospital, School of Medicine, Zhejiang University between July 2016 and June 2021, of whom 73 patients received Bu-Shen-Jian-Pi Formula treatment for 12 weeks before IVF-ET, while the other 73 did not. The clinical data were collected from the medical records of the included patients. Bone morphogenetic protein 15 (BMP15) and leukemia inhibitory factor levels in the follicular fluids were detected.

Results

After the treatment of Bu-Shen-Jian-Pi Formula, women with PCOS undergoing IVF-ET exhibited significant improvement in the fertilization (P<0.05), good-quality embryo (P<0.01), clinical pregnancy (P<0.01), and live birth (P<0.01) rates, and single birthweight in newborns (P<0.05). The expression levels of BMP15 in the follicular fluids of the women with PCOS were significantly increased after Bu-Shen-Jian-Pi Formula treatment (P<0.05).

Conclusion

This study provided preliminary evidence of a significant association of Bu-Shen-Jian-Pi Formula treatment with improved pregnancy outcomes in women with PCOS undergoing IVF-ET, partly through increasing BMP15 levels in the follicular fluids.

中药被广泛用于治疗多囊卵巢综合征(PCOS)。本研究旨在通过回顾性队列研究,探讨补肾健脾方对PCOS患者体外受精和胚胎移植(IVF-ET)妊娠结局的影响。方法选取2016年7月至2021年6月在浙江大学医学院附属女子医院接受IVF-ET治疗的146例女性PCOS患者,其中73例患者在IVF-ET前12周接受补参健脾方治疗,73例患者未接受治疗。临床资料从纳入患者的病历中收集。检测卵泡液中骨形态发生蛋白15 (Bone morphogenetic protein 15, BMP15)和白血病抑制因子水平。结果经补肾健脾方治疗后,经IVF-ET治疗的PCOS患者受精率(P<0.05)、优质胚胎率(P<0.01)、临床妊娠率(P<0.01)、活产率(P<0.01)和新生儿单胎体重(P<0.05)均有显著提高。补肾健脾方治疗后,PCOS患者卵泡液中BMP15的表达水平显著升高(p < 0.05)。结论本研究为补参健脾方治疗与PCOS患者IVF-ET妊娠结局的显著改善提供了初步证据,部分原因是通过提高卵泡液BMP15水平。
{"title":"Effects of Chinese herbal medicine on pregnancy outcomes of women with PCOS undergoing in vitro fertilization and embryo transfer: A retrospective cohort study","authors":"Minchen Dai ,&nbsp;Biwei Shi ,&nbsp;Xian Zhang ,&nbsp;Yinger Gu ,&nbsp;Fangfang Wang ,&nbsp;Jue Zhou ,&nbsp;Fan Qu","doi":"10.1016/j.eujim.2023.102317","DOIUrl":"10.1016/j.eujim.2023.102317","url":null,"abstract":"<div><h3>Introduction</h3><p>Chinese herbal medicine is widely used for treating polycystic ovary syndrome (PCOS). The present study aimed to explore the effects of Bu-Shen-Jian-Pi Formula, a Chinese herbal medicine formula, on the pregnancy outcomes of women with PCOS undergoing <em>in vitro</em> fertilization and embryo transfer (IVF-ET) based on a retrospective cohort study.</p></div><div><h3>Methods</h3><p>One hundred and forty-six females with PCOS undergoing IVF-ET were included in the study from Women's Hospital, School of Medicine, Zhejiang University between July 2016 and June 2021, of whom 73 patients received Bu-Shen-Jian-Pi Formula treatment for 12 weeks before IVF-ET, while the other 73 did not. The clinical data were collected from the medical records of the included patients. Bone morphogenetic protein 15 (BMP15) and leukemia inhibitory factor levels in the follicular fluids were detected.</p></div><div><h3>Results</h3><p>After the treatment of Bu-Shen-Jian-Pi Formula, women with PCOS undergoing IVF-ET exhibited significant improvement in the fertilization (P&lt;0.05), good-quality embryo (P&lt;0.01), clinical pregnancy (P&lt;0.01), and live birth (P&lt;0.01) rates, and single birthweight in newborns (P&lt;0.05). The expression levels of BMP15 in the follicular fluids of the women with PCOS were significantly increased after Bu-Shen-Jian-Pi Formula treatment (P&lt;0.05).</p></div><div><h3>Conclusion</h3><p>This study provided preliminary evidence of a significant association of Bu-Shen-Jian-Pi Formula treatment with improved pregnancy outcomes in women with PCOS undergoing IVF-ET, partly through increasing BMP15 levels in the follicular fluids.</p></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"65 ","pages":"Article 102317"},"PeriodicalIF":2.5,"publicationDate":"2023-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138508569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Knowledge, attitude, and practice toward complementary alternative medicine in the UAE: A cross- sectional study 阿联酋补充替代医学的知识、态度和实践:一项横断面研究
IF 2.5 4区 医学 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2023-11-03 DOI: 10.1016/j.eujim.2023.102310
Yousef Aljawarneh, Lubna Rajab, Amani Alzeyoudi, Amnah Alzeyoudi, Amira Ibrahim, Noura Alnaqbi, Salha Alkaabi

Introduction

Complementary and Alternative Medicine (CAM) encompasses utilization of traditional approaches in treating illnesses. The literature on CAM in the United Arab Emirates (UAE) shows varying awarness and practice. This study aimed to assess the knowledge, attitude, and practice towards CAM in the UAE.

Methods

The study utilized a cross-sectional design and collected data between January and March 2023 from adults in the UAE. Using convenience sampling, participants were invited to participate from public areas. A total of 964 individuals participated in the study by filling the survey electronically. Data were collecting using the CAM knowledge, attitude and practice (KAP) questionnaire. This study received ethical approval from Research Ethics and Integrity Committee at the Higher Colleges of Technology.

Results

The mean age of the participants was 31.32 years (+-10.66). The majority of the participants were Emirati (89.5 %), female (71.6 %), married (54.4 %) and held a bachelor's degree (40.4 %). Data on CAM knowledge showed that 66.7 % of the participants recognized CAM, mostly from family and friends (38 %). More than half (56.5 %) of the participants recognized the types of CAM, with Hijama as the most well known type. The majority of the participants (80.1 %) had a positive attitude toward CAM practice. Separated participants were 3.187 times less likely to exhibit positive attitude toward CAM than single participants (OR = -3.187., 95 %CI [.005, 0.345]) and Muslims were 3.517 times more likely to exhibit positive attitude toward CAM (OR = -3.517., 95 %CI [4.717, 240.673]). Moreover, 39.3 % of the participants tried CAM mostly to relieve pain (54.8 %). There was a significant correlation between age and knowledge about CAM (r = 0.147, p < 0.001) and between knowledge and attitude toward CAM (r = 0.149, p < 0.001). There was a significant correlation between attitude toward CAM and knowledge about Hijama (r = 0.136, p < 0.001), acupuncture (r = 0.192, p < 0.001), dietary supplements (r = 0.180, p < 0.001), and herbal medicine (r = 0.161, p < 0.001).

Conclusion

In the UAE, there is considerable knowledge and acceptance of CAM. Recommendations are geared toward the involvement of healthcare professionals in CAM prescription and control. Community awareness about CAM is recommended to bridge the gap between safety, risks and benefits.

补充替代医学(CAM)包括利用传统方法治疗疾病。阿拉伯联合酋长国(UAE)关于CAM的文献显示了认识和实践的差异。本研究旨在评估阿联酋对CAM的知识、态度和实践。该研究采用了横断面设计,并收集了2023年1月至3月期间阿联酋成年人的数据。采用方便抽样的方法,邀请参与者从公共区域参与。共有964人通过电子填写调查问卷参与了这项研究。采用CAM知识、态度和实践(KAP)问卷收集数据。本研究获得了高等技术学院研究伦理与诚信委员会的伦理批准。参与者的平均年龄为31.32岁(±10.66岁)。大多数参与者是阿联酋人(89.5%),女性(71.6%),已婚(54.4%),拥有学士学位(40.4%)。关于CAM知识的数据显示,66.7%的参与者认识CAM,主要来自家人和朋友(38%)。超过一半(56.5%)的参与者认识到CAM的类型,其中Hijama是最知名的类型。大多数参与者(80.1%)对CAM实践持积极态度。分开的参与者对CAM表现出积极态度的可能性是单身参与者的3.187倍(OR=-3.187)。, 95%ci[。[005, .345])和穆斯林对CAM表现出积极态度的可能性是前者的3.517倍(OR=-3.517)。, 95%ci[4.717, 240.673])。此外,39.3%(54.8%)的参与者使用CAM主要是为了缓解疼痛。年龄与CAM知识相关(r= .147, p <.001),与CAM知识态度相关(r= .149, p <.001)。对CAM的态度与对Hijama的了解有显著相关(r =。136, p <0.001),针刺(r =。192, p <0.001),膳食补充剂(r =。180, p <0.001),草药(r =。161, p <0.001)。在阿联酋,CAM有相当多的知识和接受度。建议的目的是让医疗保健专业人员参与CAM的处方和控制。建议提高社区对CAM的认识,以弥合安全、风险和效益之间的差距。
{"title":"Knowledge, attitude, and practice toward complementary alternative medicine in the UAE: A cross- sectional study","authors":"Yousef Aljawarneh,&nbsp;Lubna Rajab,&nbsp;Amani Alzeyoudi,&nbsp;Amnah Alzeyoudi,&nbsp;Amira Ibrahim,&nbsp;Noura Alnaqbi,&nbsp;Salha Alkaabi","doi":"10.1016/j.eujim.2023.102310","DOIUrl":"10.1016/j.eujim.2023.102310","url":null,"abstract":"<div><h3>Introduction</h3><p>Complementary and Alternative Medicine (CAM) encompasses utilization of traditional approaches in treating illnesses. The literature on CAM in the United Arab Emirates (UAE) shows varying awarness and practice. This study aimed to assess the knowledge, attitude, and practice towards CAM in the UAE.</p></div><div><h3>Methods</h3><p>The study utilized a cross-sectional design and collected data between January and March 2023 from adults in the UAE. Using convenience sampling, participants were invited to participate from public areas. A total of 964 individuals participated in the study by filling the survey electronically. Data were collecting using the CAM knowledge, attitude and practice (KAP) questionnaire. This study received ethical approval from Research Ethics and Integrity Committee at the Higher Colleges of Technology.</p></div><div><h3>Results</h3><p>The mean age of the participants was 31.32 years (+-10.66). The majority of the participants were Emirati (89.5 %), female (71.6 %), married (54.4 %) and held a bachelor's degree (40.4 %). Data on CAM knowledge showed that 66.7 % of the participants recognized CAM, mostly from family and friends (38 %). More than half (56.5 %) of the participants recognized the types of CAM, with Hijama as the most well known type. The majority of the participants (80.1 %) had a positive attitude toward CAM practice. Separated participants were 3.187 times less likely to exhibit positive attitude toward CAM than single participants (OR = -3.187., 95 %CI [.005, 0.345]) and Muslims were 3.517 times more likely to exhibit positive attitude toward CAM (OR = -3.517., 95 %CI [4.717, 240.673]). Moreover, 39.3 % of the participants tried CAM mostly to relieve pain (54.8 %). There was a significant correlation between age and knowledge about CAM (<em>r</em> = 0.147, <em>p</em> &lt; 0.001) and between knowledge and attitude toward CAM (<em>r</em> = 0.149, <em>p</em> &lt; 0.001). There was a significant correlation between attitude toward CAM and knowledge about Hijama (<em>r</em> = 0.136, <em>p</em> &lt; 0.001), acupuncture (<em>r</em> = 0.192, <em>p</em> &lt; 0.001), dietary supplements (<em>r</em> = 0.180, <em>p</em> &lt; 0.001), and herbal medicine (<em>r</em> = 0.161, <em>p</em> &lt; 0.001).</p></div><div><h3>Conclusion</h3><p>In the UAE, there is considerable knowledge and acceptance of CAM. Recommendations are geared toward the involvement of healthcare professionals in CAM prescription and control. Community awareness about CAM is recommended to bridge the gap between safety, risks and benefits.</p></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"64 ","pages":"Article 102310"},"PeriodicalIF":2.5,"publicationDate":"2023-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135411543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A cross-sectional study of reporting guidelines for clinical studies in Traditional Chinese Medicine 中医临床研究报告指南的横断面研究
IF 2.5 4区 医学 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2023-11-03 DOI: 10.1016/j.eujim.2023.102315
Yuting Duan , Zhirui Xu , Pinge Zhao , Juexuan Chen , Yanfang Ma , Lin Yu

Introduction

Reporting guidelines (RGs) provide the minimum information for inclusion to ensure that research reports can be understood by readers, reproduced or otherwise utilized by other researchers, or guide decisions by clinicians. The Reporting Guidelines for Clinical Studies in Traditional Chinese Medicine (RGCS-TCM) were established to guide the development of reporting standardization of clinical studies in Traditional Chinese Medicine (TCM). However, the characteristics and methodological quality of existing RGCS-TCM are yet to be investigated. We therefore performed a cross-sectional study to identify and evaluate the adequacy of RGCS-TCM and propose recommendations to optimize the development standards and future directions for RGCS-TCM.

Methods

Seven databases including MEDLINE, Excerpta Medica Database (EMBASE), the Allied and Complementary Medicine Database (AMED), Chinese Biomedical Literature Service System (CBM), China National Knowledge Infrastructure (CNKI), Wanfang Data and VIP Chinese Medical Journal Database, the EQUATOR network website, tracking references to included studies, and Google Scholar were searched up to 20th Oct 2023 for RGCS-TCM. The characteristics of included RGCS-TCM were summarized. The methodological quality of included RGCS-TCM were critically appraised.

Results

Thirty published RGCS-TCM and six registered (under development) RGCS-TCM for different types of studies were included. Nine RGCS-TCM did not use a consensus method and lacked a consensus process, and fourteen RGCS-TCM failed to retrieve and use existing relevant evidence and lacked preliminary systematic reviews. Thirteen RGs had a relatively complete research and development process, which met the 3 basic criteria for determining high-quality RGs. Most RGCS-TCM reported the details of 1) rationale of TCM (10/15, 66.7 %), 2) reason for selected certain type of TCM intervention (9/15, 60.0 %), 3) diagnosis of TCM conditions (9/15, 60.0 %), 4) details about the intervention and its controls (13/15, 86.7 %), 5) dynamic changes of Pattern Differentiation and Treatment (2/15, 13.3 %), 6) outcome assessment specifically linked with TCM (8/15, 53.3 %), and 7) potential side effects related to TCM (4/15, 26.7 %).

Conclusion

There are opportunities to rationalise and improve the quality of existing RGCS-TCM and reduce research waste. Further research is indicated to investigate the barriers and facilitators for optimizing the development and application of RGCS-TCM.

报告指南(RGs)提供纳入的最低信息,以确保研究报告可以被读者理解、复制或其他研究人员以其他方式使用,或指导临床医生的决策。制定《中医药临床研究报告指南》(RGCS-TCM),以指导中医药临床研究报告规范化工作的开展。然而,现有RGCS-TCM的特点和方法学质量还有待研究。因此,我们进行了一项横断面研究,以确定和评估RGCS-TCM的充分性,并提出优化RGCS-TCM的发展标准和未来方向的建议。方法截至2023年10月20日,检索MEDLINE、EMBASE、AMED、中国生物医学文献服务系统(CBM)、中国知网(CNKI)、万方数据和VIP中国医学期刊数据库、EQUATOR网络网站、纳入研究的追踪文献、谷歌Scholar等7个数据库,检索RGCS-TCM。总结了纳入RGCS-TCM的特点。对纳入的RGCS-TCM的方法学质量进行了批判性评价。结果纳入30个已发表的RGCS-TCM和6个已注册(正在开发)的RGCS-TCM用于不同类型的研究。9篇RGCS-TCM未采用共识方法,缺乏共识过程,14篇RGCS-TCM未能检索和使用现有的相关证据,缺乏初步的系统评价。13个RGs的研发过程相对完整,符合确定高质量RGs的3个基本标准。大多数RGCS-TCM报告了1)中医的基本原理(10/15,66.7%),2)选择某种中医干预类型的原因(9/15,60.0%),3)中医病症的诊断(9/15,60.0%),4)干预及其对照的细节(13/15,86.7%),5)辨证论治的动态变化(2/15,13.3%),6)与中医相关的结局评估(8/15,53.3%),7)与中医相关的潜在副作用(4/15,26.7%)。结论改进现有RGCS-TCM的质量,减少科研浪费是有机会的。进一步研究RGCS-TCM优化开发和应用的障碍和促进因素。
{"title":"A cross-sectional study of reporting guidelines for clinical studies in Traditional Chinese Medicine","authors":"Yuting Duan ,&nbsp;Zhirui Xu ,&nbsp;Pinge Zhao ,&nbsp;Juexuan Chen ,&nbsp;Yanfang Ma ,&nbsp;Lin Yu","doi":"10.1016/j.eujim.2023.102315","DOIUrl":"https://doi.org/10.1016/j.eujim.2023.102315","url":null,"abstract":"<div><h3>Introduction</h3><p>Reporting guidelines (RGs) provide the minimum information for inclusion to ensure that research reports can be understood by readers, reproduced or otherwise utilized by other researchers, or guide decisions by clinicians. The Reporting Guidelines for Clinical Studies in Traditional Chinese Medicine (RGCS-TCM) were established to guide the development of reporting standardization of clinical studies in Traditional Chinese Medicine (TCM). However, the characteristics and methodological quality of existing RGCS-TCM are yet to be investigated. We therefore performed a cross-sectional study to identify and evaluate the adequacy of RGCS-TCM and propose recommendations to optimize the development standards and future directions for RGCS-TCM.</p></div><div><h3>Methods</h3><p>Seven databases including MEDLINE, Excerpta Medica Database (EMBASE), the Allied and Complementary Medicine Database (AMED), Chinese Biomedical Literature Service System (CBM), China National Knowledge Infrastructure (CNKI), Wanfang Data and VIP Chinese Medical Journal Database, the EQUATOR network website, tracking references to included studies, and Google Scholar were searched up to 20<sup>th</sup> Oct 2023 for RGCS-TCM. The characteristics of included RGCS-TCM were summarized. The methodological quality of included RGCS-TCM were critically appraised.</p></div><div><h3>Results</h3><p>Thirty published RGCS-TCM and six registered (under development) RGCS-TCM for different types of studies were included. Nine RGCS-TCM did not use a consensus method and lacked a consensus process, and fourteen RGCS-TCM failed to retrieve and use existing relevant evidence and lacked preliminary systematic reviews. Thirteen RGs had a relatively complete research and development process, which met the 3 basic criteria for determining high-quality RGs. Most RGCS-TCM reported the details of 1) rationale of TCM (10/15, 66.7 %), 2) reason for selected certain type of TCM intervention (9/15, 60.0 %), 3) diagnosis of TCM conditions (9/15, 60.0 %), 4) details about the intervention and its controls (13/15, 86.7 %), 5) dynamic changes of Pattern Differentiation and Treatment (2/15, 13.3 %), 6) outcome assessment specifically linked with TCM (8/15, 53.3 %), and 7) potential side effects related to TCM (4/15, 26.7 %).</p></div><div><h3>Conclusion</h3><p>There are opportunities to rationalise and improve the quality of existing RGCS-TCM and reduce research waste. Further research is indicated to investigate the barriers and facilitators for optimizing the development and application of RGCS-TCM.</p></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"64 ","pages":"Article 102315"},"PeriodicalIF":2.5,"publicationDate":"2023-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1876382023000914/pdfft?md5=03380b6d5619edc9da081b88be3597be&pid=1-s2.0-S1876382023000914-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92028700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Complex systems, complex practice, complex outcomes: A call for the development of complexity-informed implementation models (CIIM) for traditional, complementary, and integrative medicine. 复杂系统、复杂实践、复杂结果:呼吁为传统医学、补充医学和中西医结合医学开发基于复杂性的实施模式(CIIM)。
IF 2.5 4区 医学 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2023-11-03 DOI: 10.1016/j.eujim.2023.102314
Kim D. Graham, Hope Foley, Jon Adams, Amie Steel

Introduction

Implementation science is the vehicle for ensuring that research evidence informs and shapes clinical practice. However, implementation models structured along linear and mechanistic lines are not necessarily aligned with the complexity of clinical practice. In this article we explore the development and value of a complexity informed implementation model primarily for use in traditional, complementary, and integrative medicine.

Discussion

Conventional linear mechanistic models of knowledge translation may be insufficient to address the needs of real-life clinical practice. Existing implementation models may pose particular challenges for use in traditional, integrative, and complementary systems of medicine due to their holistic orientation and perspective of human organisms as whole complex systems nested within other complex systems. This paper discusses how a complexity informed implementation model, non-linear in nature and founded on iterative processes, may better reflect the complex nature of the traditional, integrative, and complementary medicine clinical encounter and patient as a complex adaptive system.

Conclusion

The emergence of complexity science provides an opportunity to re-imagine implementation models and processes to support the translation of evidence into traditional, complementary, and integrative systems of medicine. We propose a complexity-informed implementation model to better meet the complex needs of real-life clinical practice.

实施科学是确保研究证据告知和塑造临床实践的工具。然而,沿着线性和机械线结构的实施模型不一定与临床实践的复杂性相一致。在本文中,我们探讨了主要用于传统医学、补充医学和综合医学的复杂性知情实现模型的发展和价值。传统的知识转化的线性机制模型可能不足以解决现实临床实践的需要。现有的实施模式可能对传统、综合和补充医学系统的使用构成特别的挑战,因为它们的整体取向和人类有机体作为嵌套在其他复杂系统中的整体复杂系统的观点。本文讨论了基于迭代过程的非线性复杂知情实施模型如何更好地反映传统、综合和补充医学临床治疗和患者作为复杂适应系统的复杂性。复杂性科学的出现为重新设想实施模式和流程提供了机会,以支持将证据转化为传统的、互补的和综合的医学系统。我们提出了一个复杂知情的实施模式,以更好地满足现实生活中临床实践的复杂需求。
{"title":"Complex systems, complex practice, complex outcomes: A call for the development of complexity-informed implementation models (CIIM) for traditional, complementary, and integrative medicine.","authors":"Kim D. Graham,&nbsp;Hope Foley,&nbsp;Jon Adams,&nbsp;Amie Steel","doi":"10.1016/j.eujim.2023.102314","DOIUrl":"10.1016/j.eujim.2023.102314","url":null,"abstract":"<div><h3>Introduction</h3><p>Implementation science is the vehicle for ensuring that research evidence informs and shapes clinical practice. However, implementation models structured along linear and mechanistic lines are not necessarily aligned with the complexity of clinical practice. In this article we explore the development and value of a complexity informed implementation model primarily for use in traditional, complementary, and integrative medicine.</p></div><div><h3>Discussion</h3><p>Conventional linear mechanistic models of knowledge translation may be insufficient to address the needs of real-life clinical practice. Existing implementation models may pose particular challenges for use in traditional, integrative, and complementary systems of medicine due to their holistic orientation and perspective of human organisms as whole complex systems nested within other complex systems. This paper discusses how a complexity informed implementation model, non-linear in nature and founded on iterative processes, may better reflect the complex nature of the traditional, integrative, and complementary medicine clinical encounter and patient as a complex adaptive system.</p></div><div><h3>Conclusion</h3><p>The emergence of complexity science provides an opportunity to re-imagine implementation models and processes to support the translation of evidence into traditional, complementary, and integrative systems of medicine. We propose a complexity-informed implementation model to better meet the complex needs of real-life clinical practice.</p></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"64 ","pages":"Article 102314"},"PeriodicalIF":2.5,"publicationDate":"2023-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135410125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A scoping review of traditional medicinal plants used to treat acne vulgaris in Türkiye 我国治疗寻常性痤疮的传统药用植物综述
IF 2.5 4区 医学 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2023-11-01 DOI: 10.1016/j.eujim.2023.102305
Fatma Sarı , Zeynep Büşra Erarslan

Introduction

Acne vulgaris is one of the most common dermatological disorders, especially in adolescents. This study aimed to review medicinal plants used in the treatment of acne vulgaris in Türkiye which have comprehensive usage information.

Methods

Ethnobotanical studies conducted in Türkiye from 1990 to 2023 were identified through PubMed, Sciencedirect, Scopus, Google Scholar, and YOK National Thesis Center databases using standard keywords. Articles published in peer-reviewed journals, congress proceedings, and dissertations (gray literature) were included. The scientific, family, and local names; parts used; and the methods of preparation and application were extracted from 56 ethnobotanical studies. The most cited plant families, the most cited plant taxa, and the most frequently used plant parts were determined.

Results

In total, 84 taxa belonging to 67 genera and 44 families were identified as medicinal plants used to treat acne vulgaris. The families with the highest number of plants were Asteraceae (9 taxa), Rosaceae (9 taxa), Amaryllidaceae (8 taxa), Brassicaceae (3 taxa), Hypericaceae (3 taxa), Lamiaceae (3 taxa), Papaveraceae (3 taxa), and Plantaginaceae (3 taxa). The most frequently cited medicinal plants and their corresponding number of references were Urtica dioica L. (7), Juglans regia L. (7), Laurus nobilis L. (5), Plantago major L. (5), and Malva sylvestris L. (4). It was determined that the leaves were the most frequently used parts of the medicinal plants, accounting for 36 %. Infusion (29 %) was the most commonly used preparation method. Furthermore, bioactivity studies of the most cited plants were also reviewed to evaluate their efficacy in acne vulgaris.

Conclusions

This review has identified novel herbal products which may have potential for acne vulgaris treatment, although more preclinical and clinical studies are needed to confirm their activities.

寻常痤疮是最常见的皮肤病之一,尤其是在青少年中。本文旨在对我国治疗寻常痤疮的药用植物进行综述,并对其临床应用情况进行综述。方法采用标准关键词检索PubMed、Sciencedirect、Scopus、谷歌Scholar和YOK国家论文中心数据库,对1990 - 2023年发表于我国的民族植物学研究进行鉴定。文章发表在同行评议的期刊,会议记录和论文(灰色文献)被包括在内。学名、家姓和地名;部分使用;并从56份民族植物学研究中提取了其制备方法和应用方法。确定了被引次数最多的植物科、被引次数最多的植物类群和最常用的植物部位。结果共鉴定出治疗寻常痤疮的药用植物44科67属84个分类。植物数量最多的科依次为Asteraceae(9个分类群)、Rosaceae(9个分类群)、Amaryllidaceae(8个分类群)、芸苔科(3个分类群)、金丝桃科(3个分类群)、Lamiaceae(3个分类群)、Papaveraceae(3个分类群)和车前草科(3个分类群)。被引频次最高的药用植物为荨麻(Urtica dioica L.)(7)、核桃(Juglans regia L.)(7)、月桂(Laurus nobilis L.)、车前草(Plantago major L.)(5)和Malva sylvestris L.)(4),其被引频次最高的部位为药用植物叶片,占36% %。输液(29% %)是最常用的制备方法。此外,还综述了被引用最多的植物的生物活性研究,以评价其对寻常性痤疮的治疗效果。结论本综述发现了一些具有治疗寻常性痤疮潜力的新型中药制剂,但需要更多的临床前和临床研究来证实其活性。
{"title":"A scoping review of traditional medicinal plants used to treat acne vulgaris in Türkiye","authors":"Fatma Sarı ,&nbsp;Zeynep Büşra Erarslan","doi":"10.1016/j.eujim.2023.102305","DOIUrl":"https://doi.org/10.1016/j.eujim.2023.102305","url":null,"abstract":"<div><h3>Introduction</h3><p>Acne vulgaris is one of the most common dermatological disorders, especially in adolescents. This study aimed to review medicinal plants used in the treatment of acne vulgaris in Türkiye which have comprehensive usage information.</p></div><div><h3>Methods</h3><p>Ethnobotanical studies conducted in Türkiye from 1990 to 2023 were identified through PubMed, Sciencedirect, Scopus, Google Scholar, and YOK National Thesis Center databases using standard keywords. Articles published in peer-reviewed journals, congress proceedings, and dissertations (gray literature) were included. The scientific, family, and local names; parts used; and the methods of preparation and application were extracted from 56 ethnobotanical studies. The most cited plant families, the most cited plant taxa, and the most frequently used plant parts were determined.</p></div><div><h3>Results</h3><p>In total, 84 taxa belonging to 67 genera and 44 families were identified as medicinal plants used to treat acne vulgaris. The families with the highest number of plants were Asteraceae (9 taxa), Rosaceae (9 taxa), Amaryllidaceae (8 taxa), Brassicaceae (3 taxa), Hypericaceae (3 taxa), Lamiaceae (3 taxa), Papaveraceae (3 taxa), and Plantaginaceae (3 taxa). The most frequently cited medicinal plants and their corresponding number of references were <em>Urtica dioica</em> L. (7), <em>Juglans regia</em> L. (7), <em>Laurus nobilis</em> L. (5), <em>Plantago major</em> L. (5), and <em>Malva sylvestris</em> L. (4). It was determined that the leaves were the most frequently used parts of the medicinal plants, accounting for 36 %. Infusion (29 %) was the most commonly used preparation method. Furthermore, bioactivity studies of the most cited plants were also reviewed to evaluate their efficacy in acne vulgaris.</p></div><div><h3>Conclusions</h3><p>This review has identified novel herbal products which may have potential for acne vulgaris treatment, although more preclinical and clinical studies are needed to confirm their activities.</p></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"64 ","pages":"Article 102305"},"PeriodicalIF":2.5,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92028698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Machine learning-based evaluation of application value of traditional Chinese medicine clinical index and pulse wave parameters in the diagnosis of polycystic ovary syndrome 基于机器学习的中医临床指标及脉搏波参数在多囊卵巢综合征诊断中的应用价值评价
IF 2.5 4区 医学 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2023-10-14 DOI: 10.1016/j.eujim.2023.102311
Jiekee Lim , Jieyun Li , Xiao Feng , Lu Feng , Xinang Xiao , Yumo Xia , Yiqin Wang , Lin Qian , Hong Yang , Zhaoxia Xu

Introduction

Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder in women that often leads to ovulatory infertility. This study aims to establish and validate an effective predictive model for PCOS and to explore the correlation of features between patients with irregular menstruation and those with PCOS, using pulse wave parameters and traditional Chinese medicine (TCM) clinical indices.

Methods

From August 2018 to January 2022, women with irregular menstruation were enrolled in this study. Subjects who met the inclusion criteria were categorized into PCOS and non-PCOS groups based on diagnostic criteria. Pulse wave parameters and TCM clinical indices were collected by two medical professionals. After data cleaning, recursive feature elimination with cross-validation (RFECV) was used for feature selection. Four supervised machine learning classifiers were used to build PCOS prediction models, including Extra Trees (ET), Random Forest (RF), Extreme Gradient Boosting (XGB/XGBoost), and Support Vector Machine (SVM). The SHapley Additive exPlanation (SHAP) values based on the optimal model were visualized for further feature explanation.

Results

A total of 450 women with irregular periods were enrolled in the study, consisting of 294 patients with PCOS and 156 without PCOS. Based on RFECV, 31 features, including 12 pulse parameters and 19 TCM clinical indices, were selected for building prediction models. Using pulse and TCM clinical index was superior to using pulse parameters or TCM clinical index alone in prediction. SVM achieved the best PCOS prediction results (accuracy=0.837, AUC=0.878, F1 score=0.878). For pulse parameters, lower values of right As, right h4, left h1, left h3, left h5, left w/t, and higher right t5 showed an obvious positive PCOS predictive effect. Women with PCOS were more likely to experience delayed menstruation, negative emotions, a slightly jelly-like menstrual texture, higher BMI, and a TCM assessment of greasy tongue coating.

Conclusion

A PCOS prediction model based on the SVM algorithm was established and verified as the best model for distinguishing between patients with PCOS and patients without PCOS with irregular menstruation. The new prediction model that uses pulse wave parameters and TCM clinical indices offers a non-invasive and cost-effective way to diagnose PCOS, and the model provides objective evidence for TCM diagnosis.

多囊卵巢综合征(PCOS)是一种常见的女性内分泌紊乱,常导致排卵性不孕。本研究旨在通过脉搏波参数和中医临床指标,建立并验证PCOS的有效预测模型,探讨月经不调与PCOS患者特征的相关性。方法2018年8月至2022年1月,纳入月经不调的女性。符合纳入标准的受试者根据诊断标准分为多囊卵巢综合征组和非多囊卵巢综合征组。脉搏波参数和中医临床指标由2名专业医务人员采集。数据清洗后,采用递归特征消除交叉验证(RFECV)进行特征选择。采用额外树(ET)、随机森林(RF)、极端梯度增强(XGB/XGBoost)和支持向量机(SVM)四种监督式机器学习分类器构建PCOS预测模型。将基于最优模型的SHapley加性解释(SHAP)值可视化,以便进一步进行特征解释。结果共纳入450名月经不规律的女性,其中PCOS患者294例,非PCOS患者156例。基于RFECV,选取包括12个脉象参数和19个中医临床指标在内的31个特征建立预测模型。脉搏与中医临床指标联合应用在预测预后方面优于单纯应用脉搏参数或中医临床指标。SVM预测PCOS效果最好(准确率=0.837,AUC=0.878, F1评分=0.878)。对于脉冲参数,较低的右侧As、右侧h4、左侧h1、左侧h3、左侧h5、左侧w/t和较高的右侧t5具有明显的PCOS阳性预测作用。患有多囊卵巢综合征的女性更有可能经历月经延迟、负面情绪、月经质地略微像果冻一样、体重指数更高,以及中医评估的舌苔油腻。结论建立了基于SVM算法的PCOS预测模型,并验证了该模型是区分PCOS患者与月经不调的非PCOS患者的最佳模型。结合脉搏波参数和中医临床指标的预测模型为PCOS的诊断提供了一种无创、低成本的方法,为中医诊断提供了客观依据。
{"title":"Machine learning-based evaluation of application value of traditional Chinese medicine clinical index and pulse wave parameters in the diagnosis of polycystic ovary syndrome","authors":"Jiekee Lim ,&nbsp;Jieyun Li ,&nbsp;Xiao Feng ,&nbsp;Lu Feng ,&nbsp;Xinang Xiao ,&nbsp;Yumo Xia ,&nbsp;Yiqin Wang ,&nbsp;Lin Qian ,&nbsp;Hong Yang ,&nbsp;Zhaoxia Xu","doi":"10.1016/j.eujim.2023.102311","DOIUrl":"https://doi.org/10.1016/j.eujim.2023.102311","url":null,"abstract":"<div><h3>Introduction</h3><p>Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder in women that often leads to ovulatory infertility. This study aims to establish and validate an effective predictive model for PCOS and to explore the correlation of features between patients with irregular menstruation and those with PCOS, using pulse wave parameters and traditional Chinese medicine (TCM) clinical indices.</p></div><div><h3>Methods</h3><p>From August 2018 to January 2022, women with irregular menstruation were enrolled in this study. Subjects who met the inclusion criteria were categorized into PCOS and non-PCOS groups based on diagnostic criteria. Pulse wave parameters and TCM clinical indices were collected by two medical professionals. After data cleaning, recursive feature elimination with cross-validation (RFECV) was used for feature selection. Four supervised machine learning classifiers were used to build PCOS prediction models, including Extra Trees (ET), Random Forest (RF), Extreme Gradient Boosting (XGB/XGBoost), and Support Vector Machine (SVM). The SHapley Additive exPlanation (SHAP) values based on the optimal model were visualized for further feature explanation.</p></div><div><h3>Results</h3><p>A total of 450 women with irregular periods were enrolled in the study, consisting of 294 patients with PCOS and 156 without PCOS. Based on RFECV, 31 features, including 12 pulse parameters and 19 TCM clinical indices, were selected for building prediction models. Using pulse and TCM clinical index was superior to using pulse parameters or TCM clinical index alone in prediction. SVM achieved the best PCOS prediction results (accuracy=0.837, AUC=0.878, F1 score=0.878). For pulse parameters, lower values of right As, right h4, left h1, left h3, left h5, left w/t, and higher right t5 showed an obvious positive PCOS predictive effect. Women with PCOS were more likely to experience delayed menstruation, negative emotions, a slightly jelly-like menstrual texture, higher BMI, and a TCM assessment of greasy tongue coating.</p></div><div><h3>Conclusion</h3><p>A PCOS prediction model based on the SVM algorithm was established and verified as the best model for distinguishing between patients with PCOS and patients without PCOS with irregular menstruation. The new prediction model that uses pulse wave parameters and TCM clinical indices offers a non-invasive and cost-effective way to diagnose PCOS, and the model provides objective evidence for TCM diagnosis.</p></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"64 ","pages":"Article 102311"},"PeriodicalIF":2.5,"publicationDate":"2023-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1876382023000872/pdfft?md5=660b2fc308f71cadee2c86cf5a0eb5a7&pid=1-s2.0-S1876382023000872-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92028699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bloodletting therapy for primary headache: A systematic review and meta-analysis of randomized controlled trials 放血治疗原发性头痛:随机对照试验的系统回顾和荟萃分析
IF 2.5 4区 医学 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2023-10-14 DOI: 10.1016/j.eujim.2023.102312
Shuai Dong, Yi-Ying Wang, Bo Li, Shi-Bing Liang, Hui-Juan Cao

Introduction

Headache is one of the most common symptoms worldwide. This systematic review aimed to assess the effectiveness and safety of bloodletting therapy (BLT) for primary headache.

Methods

Four English databases, four Chinese databases and five trials registries were searched from inception to 2nd Sep 2022. Randomized controlled trials which compared BLT to no treatment or drugs for primary headache were included. BLT as adjunctive treatment of drugs or acupuncture was also included. Two authors extracted data and assessed the quality of trials through the Cochrane risk of bias tool 2.0 independently. Pain intensity was the primary outcome (e.g. Visual analogue scale, VAS). Meta-analysis (using RevMan 5.4.1) with random effect model was conducted when there was no serious statistical heterogeneity among trials (I²≤75 %). GRADE was used to assess the certainty of evidence.

Results

Seventeen trials involving 1123 participants were included. Types of BLT included pricking BLT, wet cupping and bloodletting puncture with plum-blossom needle. The most frequently used BLT acupoint was Tai Yang. Type of comparisons included BLT vs. drugs (n = 3), BLT plus drugs vs. drugs (n = 4) and BLT plus acupuncture vs. acupuncture (n = 10). All included trials were assessed as "high risk of bias". Results showed that BLT plus rizatriptan benzoate tablets was superior to drug alone in reducing VAS (Mean Difference (MD)=-2.07 cm, 95 % Confidence Interval (CI) -2.65 cm to -1.50 cm, P<0.00001) and increasing the number of patients with more than half pain relief (by 39 %). BLT plus acupuncture was superior to acupuncture alone (MD=-0.80 cm, 95 % CI -1.20 cm to -0.41 cm, P<0.00001) for pain relief. However, no difference was found between BLT and drugs on decreasing VAS. The certainty of the overall evidence is very low mainly due to the poor methodological quality and high heterogeneity among trials.

Conclusion

Very low certainty evidence suggests that BLT combined with acupuncture or drugs may be more effective in relieving pain of primary headache and other concomitant symptoms. Current evidence does not support confirmatory conclusions about the safety of BLT.

头痛是世界上最常见的症状之一。本系统综述旨在评估放血疗法(BLT)治疗原发性头痛的有效性和安全性。方法检索4个英文数据库、4个中文数据库和5个试验注册库。将BLT与无治疗或药物治疗原发性头痛进行比较的随机对照试验也包括在内。BLT作为药物或针灸的辅助治疗也包括在内。两位作者通过Cochrane风险偏倚工具2.0独立提取数据并评估试验质量。疼痛强度是主要观察指标(如视觉模拟评分,VAS)。当试验间统计异质性不严重(I²≤75%)时,采用随机效应模型进行meta分析(RevMan 5.4.1)。GRADE用于评估证据的确定性。结果共纳入17项试验,1123名受试者。治疗方法包括刺刺、湿拔罐和梅花针放血穿刺。最常使用的穴位是太阳。比较类型包括BLT与药物(n = 3)、BLT +药物与药物(n = 4)、BLT +针灸与针灸(n = 10)。所有纳入的试验都被评估为“高风险偏倚”。结果显示,BLT联合苯甲酸利扎曲坦片在降低VAS(平均差值(MD)=-2.07 cm, 95%可信区间(CI) -2.65 cm ~ -1.50 cm, P<0.00001)和增加一半以上疼痛缓解的患者数量(39%)方面优于单用药物。在缓解疼痛方面,BLT +针灸优于单独针灸(MD=-0.80 cm, 95% CI -1.20 cm ~ -0.41 cm, P<0.00001)。然而,在降低VAS方面,BLT与药物之间没有差异。总体证据的确定性非常低,主要是由于试验的方法学质量差和异质性高。结论极低确定性证据表明,BLT联合针灸或药物治疗可更有效地缓解原发性头痛及其他伴随症状。目前的证据并不支持关于BLT安全性的确认性结论。
{"title":"Bloodletting therapy for primary headache: A systematic review and meta-analysis of randomized controlled trials","authors":"Shuai Dong,&nbsp;Yi-Ying Wang,&nbsp;Bo Li,&nbsp;Shi-Bing Liang,&nbsp;Hui-Juan Cao","doi":"10.1016/j.eujim.2023.102312","DOIUrl":"https://doi.org/10.1016/j.eujim.2023.102312","url":null,"abstract":"<div><h3>Introduction</h3><p>Headache is one of the most common symptoms worldwide. This systematic review aimed to assess the effectiveness and safety of bloodletting therapy (BLT) for primary headache.</p></div><div><h3>Methods</h3><p>Four English databases, four Chinese databases and five trials registries were searched from inception to 2<sup>nd</sup> Sep 2022. Randomized controlled trials which compared BLT to no treatment or drugs for primary headache were included. BLT as adjunctive treatment of drugs or acupuncture was also included. Two authors extracted data and assessed the quality of trials through the Cochrane risk of bias tool 2.0 independently. Pain intensity was the primary outcome (e.g. Visual analogue scale, VAS). Meta-analysis (using RevMan 5.4.1) with random effect model was conducted when there was no serious statistical heterogeneity among trials (<em>I</em>²≤75 %). GRADE was used to assess the certainty of evidence.</p></div><div><h3>Results</h3><p>Seventeen trials involving 1123 participants were included. Types of BLT included pricking BLT, wet cupping and bloodletting puncture with plum-blossom needle. The most frequently used BLT acupoint was <em>Tai Yang</em>. Type of comparisons included BLT vs. drugs (<em>n</em> = 3), BLT plus drugs vs. drugs (<em>n</em> = 4) and BLT plus acupuncture vs. acupuncture (<em>n</em> = 10). All included trials were assessed as \"high risk of bias\". Results showed that BLT plus rizatriptan benzoate tablets was superior to drug alone in reducing VAS (Mean Difference (MD)=-2.07 cm, 95 % Confidence Interval (CI) -2.65 cm to -1.50 cm, <em>P</em>&lt;0.00001) and increasing the number of patients with more than half pain relief (by 39 %). BLT plus acupuncture was superior to acupuncture alone (MD=-0.80 cm, 95 % CI -1.20 cm to -0.41 cm, <em>P</em>&lt;0.00001) for pain relief. However, no difference was found between BLT and drugs on decreasing VAS. The certainty of the overall evidence is very low mainly due to the poor methodological quality and high heterogeneity among trials.</p></div><div><h3>Conclusion</h3><p>Very low certainty evidence suggests that BLT combined with acupuncture or drugs may be more effective in relieving pain of primary headache and other concomitant symptoms. Current evidence does not support confirmatory conclusions about the safety of BLT.</p></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"64 ","pages":"Article 102312"},"PeriodicalIF":2.5,"publicationDate":"2023-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92045550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European Journal of Integrative Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1